<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31944652</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1554-8937</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>02</Month><Day>21</Day></PubDate></JournalIssue><Title>ACS chemical biology</Title><ISOAbbreviation>ACS Chem Biol</ISOAbbreviation></Journal><ArticleTitle>Small-Molecule Antagonists of the RIG-I Innate Immune Receptor.</ArticleTitle><Pagination><MedlinePgn>311-317</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acschembio.9b00810</ELocationID><Abstract><AbstractText>The RIG-I receptor plays a key role in the vertebrate innate immune system, where it functions as a sensor for detecting infection by RNA viruses. Although agonists of RIG-I show great potential as antitumor and antimicrobial therapies, antagonists of RIG-I remain undeveloped, despite the role of RIG-I hyperstimulation in a range of diseases, including COPD and autoimmune disorders. There is now a wealth of information on RIG-I structure, enzymatic function, and signaling mechanism that can drive new drug design strategies. Here, we used the enzymatic activity of RIG-I to develop assays for high-throughput screening, SAR, and downstream optimization of RIG-I antagonists. Using this approach, we have developed potent RIG-I antagonists that interact directly with the receptor and which inhibit RIG-I signaling and interferon response in living cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rawling</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Inflammatix, Inc , Burlingame , California 94010 , United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagdmann</LastName><ForeName>G Erik</ForeName><Initials>GE</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Molecular, Cellular and Developmental Biology , Yale University , New Haven , Connecticut 06520 , United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potapova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Molecular, Cellular and Developmental Biology , Yale University , New Haven , Connecticut 06520 , United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pyle</LastName><ForeName>Anna Marie</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-9045-8872</Identifier><AffiliationInfo><Affiliation>Department of Molecular, Cellular and Developmental Biology , Yale University , New Haven , Connecticut 06520 , United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute , New Haven , Connecticut 06520 , United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI089826</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Chem Biol</MedlineTA><NlmUniqueID>101282906</NlmUniqueID><ISSNLinking>1554-8929</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C487115">4-hydroxy-3,3-dimethyl-2H-benzo(g)indole-2,5(3H)-dione</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C452820">DDX58 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D000071457">DEAD Box Protein 58</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000072283">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000071457">DEAD Box Protein 58</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D057166">High-Throughput Screening Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015394">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011971">Receptors, Immunologic</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013329">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31944652</ArticleId><ArticleId IdType="doi">10.1021/acschembio.9b00810</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE"><PMID Version="1">32984021</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial.</ArticleTitle><Pagination><MedlinePgn>1589</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2020.01589</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) has poor prognosis. Sorafenib/lenvatinib is recommended as the first-line therapy in these patients currently, with unsatisfactory response and survival benefit reported. Radiotherapy (RT) is increasingly utilized in advanced HCC and is considered an alternative option for HCC patients with PVTT. Combined treatment of RT and locoregional treatments such as transarterial chemoembolization shows promising results. However, the efficacy and safety for combined treatment of RT and systemic therapy have not been reported and thus warrant further studies. This prospective clinic trial aims at evaluating the efficacy and safety of stereotactic body RT (SBRT) combined with camrelizumab and apatinib in HCC patients with PVTT.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">This multicenter, open-label, randomized controlled trial will enroll 264 HCC patients with PVTT who have not received systemic therapy previously. Stratification of patients will be based on the presence or absence of extrahepatic metastasis and level of AFP (AFP &#8805; 400 or &lt;400 ng/mL) and randomly assigned 1:1 to study and control groups. Patients in study group will receive SBRT (95% PTV 36-40 Gy/6-8 Gy), camrelizumab (200 mg every 3 weeks), and apatinib (250 mg every day), and patients in control group will receive camrelizumab (200 mg every 2 weeks) and apatinib (250 mg every day). Patients will be followed up for 1.5 to 3.5 years since the start of therapy. We will use overall survival as the primary endpoint and progression-free survival, objective response rate, disease control rate, adverse events, and quality of life as the secondary endpoints.</AbstractText><AbstractText Label="Discussion" NlmCategory="UNASSIGNED">This study will be the first randomized controlled trial to assess the efficacy and safety of SBRT combined with camrelizumab and apatinib for HCC patients with PVTT. The results may help establish a new standard first-line therapy for these patients.</AbstractText><AbstractText Label="Trial Registration" NlmCategory="UNASSIGNED">Chinese Clinical Trial Registration No. ChiCTR1900027102.</AbstractText><AbstractText Label="Date of Registration" NlmCategory="UNASSIGNED">October 31, 2019.</AbstractText><CopyrightInformation>Copyright &#169; 2020 Hu, Qin, Li, Zhang and Xue.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Statistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, The First People's Hospital of Jingzhou, Jingzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HCC</Keyword><Keyword MajorTopicYN="N">PVTT</Keyword><Keyword MajorTopicYN="N">SBRT</Keyword><Keyword MajorTopicYN="N">apatinib</Keyword><Keyword MajorTopicYN="N">camrelizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>28</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32984021</ArticleId><ArticleId IdType="doi">10.3389/fonc.2020.01589</ArticleId><ArticleId IdType="pmc">PMC7479183</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Semin Liver Dis. 2018 Aug;38(3):242-251</Citation><ArticleIdList><ArticleId IdType="pubmed">30041276</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12909223</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2017 Apr 12;9(385):</Citation><ArticleIdList><ArticleId IdType="pubmed">28404866</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2012 May;142(6):1264-1273.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">22537432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Gastroenterol Hepatol. 2019 Sep;4(9):721-730</Citation><ArticleIdList><ArticleId IdType="pubmed">31387735</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2019 Aug 20;37(24):2141-2151</Citation><ArticleIdList><ArticleId IdType="pubmed">31283409</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncotarget. 2017 Jan 31;8(5):8867-8876</Citation><ArticleIdList><ArticleId IdType="pubmed">27780939</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604</Citation><ArticleIdList><ArticleId IdType="pubmed">31439937</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2019 Jan 14;9:3107</Citation><ArticleIdList><ArticleId IdType="pubmed">30692993</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):432-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15667964</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Oncol. 2018 May 1;4(5):661-669</Citation><ArticleIdList><ArticleId IdType="pubmed">29543938</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 2018 Oct;129(1):136-142</Citation><ArticleIdList><ArticleId IdType="pubmed">29548558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatology. 2018 Jan;67(1):358-380</Citation><ArticleIdList><ArticleId IdType="pubmed">28130846</ArticleId></ArticleIdList></Reference><Reference><Citation>Liver Int. 2017 Jan;37(1):90-100</Citation><ArticleIdList><ArticleId IdType="pubmed">27317941</ArticleId></ArticleIdList></Reference><Reference><Citation>CA Cancer J Clin. 2018 Nov;68(6):394-424</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2019 Feb 21;25(7):789-807</Citation><ArticleIdList><ArticleId IdType="pubmed">30809080</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2019 Aug;41(8):1463-1476</Citation><ArticleIdList><ArticleId IdType="pubmed">31303279</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2019 Jan 15;25(2):515-523</Citation><ArticleIdList><ArticleId IdType="pubmed">30348638</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1155-63</Citation><ArticleIdList><ArticleId IdType="pubmed">18760547</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hepatol. 2018 Jul;69(1):182-236</Citation><ArticleIdList><ArticleId IdType="pubmed">29628281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatobiliary Pancreat Dis Int. 2019 Dec;18(6):505-510</Citation><ArticleIdList><ArticleId IdType="pubmed">31551142</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Oncol. 2019 Jul;42(7):555-563</Citation><ArticleIdList><ArticleId IdType="pubmed">31135382</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiat Oncol. 2018 Sep 25;13(1):188</Citation><ArticleIdList><ArticleId IdType="pubmed">30253783</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatology. 2019 May;69(5):2076-2090</Citation><ArticleIdList><ArticleId IdType="pubmed">30586158</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>